Hepatitis Treatment News
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News

May 26, 2015
World Health Organization Throws Weight Behind Hep C Treatments
The World Health Organization (WHO) has added the new hepatitis C medications to its Model List of Essential Medicines.
May 21, 2015
Losing Weight Is Linked to Improvement in NASH
People with nonalcoholic steatohepatitis (NASH) who lose significant body weight are likely to experience improvements in their disease condition.
NASH Increases Risk of Death by 50% Over NAFLD
Non-alcoholic steatohepatitis (NASH) is associated with a 50 percent greater risk of death than non-alcoholic fatty liver disease (NAFLD).
Diabetes Drug Appears to Clear NASH in Some Cases
The diabetes drug Victoza (liraglutide) has apparently eliminated non-alcoholic steatohepatitis (NASH) in a significant proportion of those treated in a recent trial.
May 20, 2015
Fatty Liver Disease Rising as Liver Cancer Cause
With a quarter of Americans living with the condition, fatty liver disease is increasingly a cause of liver cancer.
Harvoni Boasts Near-Perfect Hep C Cure Rates in Cirrhotics
Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir), with or without ribavirin, cures 92 to 100 percent of people with genotype 1 of hepatitis C and cirrhosis.
Early Study of Hepatitis B Immune Therapy Raises Cure Hopes
A new immune therapy targeting hepatitis B has shown promise in an animal study.
Screening for Hep C is Vital to Catch Progressing Liver Damage
Knowing your hepatitis C status has no apparent effect on the likelihood of your developing advanced liver fibrosis.
May 19, 2015
New Treatment Could Fight Liver Cancer
Researchers have identified a new therapy that could help treat liver cancer in a certain subset of people with the disease.
May 18, 2015
Curing Hepatitis C Likely Spells Substantial Economic Benefit
Treating all people with hepatitis C virus in the United States and five European nations could lead an economic benefit of $3.2 billion per year.
Hep C Treatment Can Help Those With Advanced Liver Disease
Various combinations of Sovaldi (sofosbuvir), Olysio (simeprevir) and ribavirin can cure hepatitis C among those with decompensated cirrhosis.
Diabetes Drug May Help Treat Non-Alcoholic Liver Disease
An investigational anti-diabetes drug may be an option for treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
May 15, 2015
Daclatasvir Plus Sovaldi Shows Promise Curing Hard-to-Treat Hep C
Daclatasvir and Sovaldi, with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatitis C virus.
May 14, 2015
Central Appalachian Jump in Hep C Linked to Opioid Use
A rise in opioid dependency and in the rate of injection drug use in four central Appalachian states has occurred in tandem with a rising hepatitis C incidence.
Cure for Almost All Hep C-Positive Liver Transplantees
Daclatasvir and Sovaldi, with or without ribavirin, offer near-perfect hepatitis C cure rates among those who have received a liver transplant.
May 13, 2015
Hepatitis C Is a Risk Factor for Heart Disease
People with hepatitis C are at increased risk of cardiovascular disease.
May 12, 2015
Good Results for BMS’s Triple-Drug Hep C Genotype 1 Treatment
Bristol-Myers Squibb’s daclatasvir, asunaprevir and beclabuvir cured high rates of hepatitis C among those with genotype 1 without cirrhosis.
One in Five People With Hep C Likely Have Advanced Liver Disease
A significant proportion of people with undiagnosed hepatitis C likely have advanced liver disease and are in relatively urgent need of treatment.
May 11, 2015
Olysio and Sovaldi Cures 84 Percent of Cirrhotic Hep C Genotype 1’s
In a recent trial, Olysio and Sovaldi cured a moderately high proportion of those with genotype 1 of hepatitis C who had cirrhosis.
Hepatitis C Stigma Can Be Severe
Half of people with hepatitis B or C viruses report experiencing discrimination, and one in four say family members have skirted physical contact because of their infection.
May 08, 2015
Olysio-Sovaldi Combo Cures High Rates of Hep C Genotype 1
Twelve weeks of Olysio and Sovaldi boasted near-perfect cure results treating non-cirrhotic people with genotype 1 of hepatitis C, in a recent trial.
May 07, 2015
Harvoni Beats Hep C Among Those With Advanced Liver Disease
Harvoni and ribavirin cures hepatitis C at mostly high rates among those with decompensated cirrhosis or recurrent hep C after a liver transplant.
May 06, 2015
Could a Cancer Drug Cure Hepatitis B?
A cancer drug has shown promise as a potential cure for hepatitis B.
Daclatasvir and Sovaldi Cure High Rates of Genotype 1 of Hep C
Daclatasvir and Sovaldi, with or without ribavirin, cures high rates of people with genotype 1 of hepatitis C, according to preliminary data in a recent trial.
May 05, 2015
Joint Pain Flares Among People With HIV, Hepatitis C or Both
People with HIV and hepatitis C virus, as well as those who are coinfected with both viruses, report high levels of joint pain.
Global Hep B Could Plummet With More Vaccination and Treatment
Drastically raising the global rates of hepatitis B vaccination and treatment could deal a major blow to the disease.
Harvoni Cures High Rates of Genotypes 4 and 5 of Hepatitis C
Harvoni posted excellent results in curing genotypes 4 and 5 of hepatitis, including among those with cirrhosis, in a recent small trial.
May 04, 2015
Success for 8 Weeks of Grazoprevir/Elbasvir Plus Sovaldi
Eight weeks of Merck’s grazoprevir/elbasvir, plus Gilead Sciences’ Sovaldi cured high rates of people with genotype 1 or 3 of hepatitis C in a small trial.
Retreatment With 24 Weeks of Harvoni Often Cures Hepatitis C
People with genotype 1 of hepatitis C who have failed Harvoni have a good chance of a cure from a second round of the drug lasting 24 weeks.
Statins Appear Helpful to Hep C-Related Compensated Cirrhosis
Statins were found to be significantly beneficial to treating compensated cirrhosis among people with hepatitis C in a recent trial.
Putting Off Hep C Treatment Raised Risks With Older Treatments
Delaying hepatitis C treatment until liver damage was more advanced lowered the likelihood of a cure among interferon treatments in the pre-direct-acting antiviral era.
May 03, 2015
Viekira Pak Shows Promise for Kidney-Impaired People With Hep C
AbbVie’s Viekira Pak, with or without ribavirin, appears to work very well curing genotype 1 of hepatitis C.
Europe Is Behind the Eight Ball in Combatting Viral Hepatitis
Numerous European nations are in a poor position to combat hepatitis B and C viruses, given their inadequate systems to monitor viral hepatitis and to assess the effectiveness of interventions.

May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008


Current Issue
Hep Stories
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Would you travel abroad for cheaper hep C treatment?

Hepatitis C Reader Survey
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.